期刊名称：CLINICAL DRUG INVESTIGATION
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aim & Scope
The Journal's aim is rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs.
The journal includes:
- Clinical trials, outcomes research, clinical pharmacoeconomic studies, pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs.
- Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice.
- Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed.
Short communications and case study reports that meet the above criteria will also be considered.
Please contact us at cdi@adis.co.nz.
Instructions to Authors
Instructions for Authors for Preparation of Manuscripts
for Clinical Drug Investigation
General Information
Journal Aim and Scope
The Journal's aim is rapid publication of original research covering all phases of clinical drug
development and therapeutic use of drugs.
The journal includes:
?Clinical trials, outcomes research, clinical pharmacoeconomic studies and
pharmacoepidemiological studies with a strong link to optimum prescribing practice for a
drug or group of drugs.
?Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to
clinical practice.
Authorship and Contributorship Criteria
Each author should have participated sufficiently in the work to take public responsibility for
appropriate portions of the content. Authors should meet all the following criteria: (i) conceived
and planned the work that led to the manuscript or played an important role in the acquisition,
analysis and interpretation of the data or both; (ii) wrote the paper and/or made substantive
suggestions for revision and; (iii) approved the final submitted version. The corresponding author
takes responsibility for the work as a whole, from inception to the published manuscript, and will
be responsible for sign-off of the final proofs prior to publication.
The Author Declaration Form is attached (see Appendix D) and is also available on the journal
website. The journal will not publish a manuscript unless it has received a signed copy of this
form from all authors. Any change in authors and/or contributors after initial submission must be
approved by all authors. This applies to additions, deletions, change in order of the authors, or
contributions being attributed differently. Any alterations must be explained to the editor.
The corresponding author must provide a statement indicating the names and contributions of
all persons who have contributed to the work reported in the manuscript but who do not fulfil
authorship criteria. This information will be published in an Acknowledgments section of the
paper. Authors should obtain written permission from individuals to be named in the
Acknowledgments section.
Conflict of Interest Statement for Authors
The potential for conflict of interest arises when authors have personal or financial relationships
that could influence their actions. All authors should indicate potential conflicts of interest,
including specific financial interests relevant to the subject of their manuscript, on the in section
F of the Author Declaration Form (see Appendix D). To prevent ambiguity, authors must state
explicitly whether potential conflicts do or do not exist. Details of relevant conflicts of interest (or
the lack of) must be declared in the Acknowledgments section of the manuscript for all authors.
Role of the Funding Source
All sources of funding should be declared in the Acknowledgements section of the manuscript.
Authors of studies are required to confirm that the paper is an accurate representation of the
study results and they must describe the role of the study sponsor(s), if any, in: (i) study design;
(ii) the collection, analysis and interpretation of data; (iii) the writing of the report; and (iv) the
decision to submit the paper for publication. If the authors?work was independent of the funders,
the authors should state this.
Clinical Drug Investigation Instructions for Authors
Manuscript Submission
Please note that all material submitted for publication must be submitted exclusively to Clinical
Drug Investigation. To submit a manuscript to the journal you will need to log onto the AdisOnline
site (www.adisonline.com) and following the links and instructions to our online submission system
(Adis Editorial Manager; http://adis.edmgr.com). Step-by-step instructions are available on the
website.
Manuscripts must be prepared and submitted in the manner described in “Uniform
Requirements for Manuscripts Submitted to Biomedical Journals?(see http://www.icmje.org/).
If you are unable to submit through the Editorial Manager site, e-mail us at journals@adis.co.nz or
cdi@adis.co.nz, and include the journal name and “Article Submission?in the subject line.
Manuscript Format and Style
Clinical Drug Investigation publishes various types of original research, including case reports (see
Appendix B for outlines and Appendix C for recommended guidelines), and letters to the editor.
Authors should specify in their covering letter the category they prefer for their submission.
In general, manuscripts should be prepared and paginated in the following manner:
A. Title page: include title, authors (please also provide forename[s]) and institutions for
each author where the work was done (indicating the city), and a condensed running title
of not more than 50 characters including spaces.
B. Acknowledgments: See Appendix A, point 8.
C. Name and address for correspondence: Mailing address plus telephone and fax
number. An e-mail address should also be supplied, but will not be published without your
permission.
D. Table of contents
E. Figure captions
F. Abstract: The abstract should succinctly highlight, in an informative manner, the specific
important points addressed in the main body of the text; it should not just describe the
general areas covered in the manuscript. The journal style is to not cite references in the
abstract so as to provide a discrete synopsis of the article. The length can be up to ~400-
500 words. Authors of original research should submit a structured abstract as outlined in
Appendix C.
G. Text pages (with page numbering)
H. Conclusion
I. Footnotes
J. Reference list (in Vancouver style)
K. Tables (begin each table on a new page)
L. Figures (place each figure in a separate file)
Please put sections A-K into a single file.
Abbreviations and Symbols
Use SI symbols and recognised abbreviations for units of measurement. The first time an
abbreviation appears it should be preceded by the full name for which it stands, followed by the
abbreviation in parentheses. Generally, abbreviations should be avoided as much as possible, and
used only when the full term would make the text unduly cumbersome.
Drug Names
Generic names (International Nonproprietary Names [INN] or United States Adopted names
[USAN]) must be used. In review papers, brand names or trade names can be used in selected
instances, e.g. when use of the generic name would be impractical or ambiguous. In original
research a therapeutic intervention should be named by both its generic name and trade name
(along with the manufacturer and location) in the methods section in order to precisely identify the
product investigated.
Instructions to Authors
桌
Editorial Board
Editorial Board
- G.W. Amsden, Cooperstown, NY, USA
- E. Battegay, Basle, Switzerland
- E. Beghi, Milan, Italy
- L. Bertilsson, Huddinge, Sweden
- G. Bianchi Porro, Milan, Italy
- S.S. Bloomfield, Cincinnati, OH, USA
- S.G. Carruthers, London, ONT, Canada
- E. Christophers, Kiel, Germany
- M.J. Eadie, Brisbane, QLD, Australia
- D.E. Furst, Los Angeles, CA, USA
- H. Giamarellou, Athens, Greece
- J.M.T. Hamilton-Miller, London, England
- P.D. Home, Newcastle upon Tyne, England
- F. Horak, Vienna, Austria
- T. Itoh, Osaka, Japan
- N.M. Kaplan, Dallas, TX, USA
- G.L. Kearns, Kansas City, MO, USA
- C.R. Kumana, Hong Kong, China
- M. Lader, London, England
- A. Lahiri, Harrow, England
- S.K. Lam, Hong Kong, China
- K. McCormack, London, England
- H.I. Maibach, San Francisco, CA, USA
- R. Marshall, Auckland, New Zealand
- T.O. Morgan, Melbourne, Vic., Australia
- G.L. Morris III, Milwaukee, WI, USA
- F.M. Muggia, Los Angeles, CA, USA
- S. Pavlovsky, Buenos Aires, Argentina
- E. Perucca, Pavia, Italy
- B.N.C. Prichard, London, England
- C.V.S. Ram, Dallas, TX, USA
- S.C. Schachter, Boston, MA, USA
- M.W. Simon, Lexington, KY, USA
- P. Tugwell, Ottawa, ONT, Canada
- C.J. van Boxtel, Nigtevecht, The Netherlands
- H.A.I.M. van Leusden, Nijmegen, The Netherlands
- M.M. Weinberger, Iowa City, IA, USA
- H.B. Wong, Singapore
- V. Wong, Hong Kong, China
|
